MSF's publications are an expression of our belief in the principle of témoignage, or bearing witness, and the belief that we are accountable to those we work for and with. Sharing news about our activities and reflecting on them, offering critiques when necessary, are therefore crucial aspects of our work.

View and download these publications below.

To view the U.S. Annual Reports or International Activity Reports, please visit the Annual Reports page.

Country/Region

April 27, 2016

MSF hands over global petition as volunteers place 2,500 flowers in front of Pfizer’s headquarters in New York, representing the number of kids who die of pneumonia each day.

February 26, 2016

New York/New Delhi—In proceedings that could have major implications for millions of people waiting for affordable access to a lifesaving hepatitis C drug, the Indian Patent Office this week began hearings to determine whether US pharmaceutical company Gilead Sciences deserves a patent for sofosbuvir, a hepatitis C drug for which the company currently charges $1,000 per pill in the US.

March 23, 2011

Across North Africa and the Middle East, MSF has been supplying and assisting hospitals and health structures where medical staff face increased numbers of injured people.

April 27, 2016

MSF hands over global petition as volunteers place 2,500 flowers in front of Pfizer’s headquarters in New York, representing the number of kids who die of pneumonia each day.

February 26, 2016

New York/New Delhi—In proceedings that could have major implications for millions of people waiting for affordable access to a lifesaving hepatitis C drug, the Indian Patent Office this week began hearings to determine whether US pharmaceutical company Gilead Sciences deserves a patent for sofosbuvir, a hepatitis C drug for which the company currently charges $1,000 per pill in the US.

March 23, 2011

Across North Africa and the Middle East, MSF has been supplying and assisting hospitals and health structures where medical staff face increased numbers of injured people.